Long Non-Coding RNA MALAT1 as a Detection and Diagnostic Molecular Marker in Various Human Cancers: A Pooled Analysis Based on 3255 Subjects

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.2159031912902
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.2155130620402
   PubMed Web of Science ®Google Scholar
• Poon RT. Prevention of recurrence after resection of hepatocellular carcinoma: a daunting challenge. Hepatology. 2011;54(3):757–759. doi:10.1002/hep.2456921793027
   PubMed Web of Science ®Google Scholar
• Cree IA, Kurbacher CM, Lamont A, Hindley AC, Love S. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physicians? Choice in patients with recurrent platinum-resistant ovarian cancer. Anticancer Drugs. 2007;18(9):1093–1101. doi:10.1097/CAD.0b013e3281de727e17704660
   PubMed Web of Science ®Google Scholar
• Yang K, Park W, Huh SJ, Bae DS, Kim BG, Lee JW. Clinical outcomes in patients treated with radiotherapy after surgery for cervical cancer. Radiat Oncol J. 2017;35(1):39–47. doi:10.3857/roj.2016.0189327927011
   PubMed Web of Science ®Google Scholar
• Car LT, Papachristou N, Urch C, et al. Preventing delayed diagnosis of cancer: clinicians’ views on main problems and solutions. J Glob Health. 2016;6(2):020901. doi:10.7189/jogh.06.02090128028437
   PubMed Web of Science ®Google Scholar
• Gildea TR, DaCosta Byfield S, Hogarth DK, Wilson DS, Quinn CC. A retrospective analysis of delays in the diagnosis of lung cancer and associated costs. Clinicoecon Outcomes Res. 2017;9:261–269. doi:10.2147/CEOR.S13225928553128
   PubMed Web of Science ®Google Scholar
• Bradley CJ. Cancer, Financial Burden, and Medicare Beneficiaries. J Clin Oncol. 2017;35(22):2461–2462. doi:10.1200/JCO.2017.73.187728562166
   PubMed Web of Science ®Google Scholar
• Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77(15):3965–3981. doi:10.1158/0008-5472.CAN-16-263428701486
   PubMed Web of Science ®Google Scholar
• Mercer TR, Mattick JS. Structure and function of long noncoding RNAs in epigenetic regulation. Nat Struct Mol Biol. 2013;20(3):300–307. doi:10.1038/nsmb.248023463315
   PubMed Web of Science ®Google Scholar
• Beermann J, Piccoli MT, Viereck J, Thum T. Non-coding RNAs in development and disease: background, mechanisms, and therapeutic approaches. Physiol Rev. 2016;96(4):1297–1325. doi:10.1152/physrev.00041.201527535639
   PubMed Web of Science ®Google Scholar
• Xie CR, Wang F, Zhang S, et al. Long noncoding RNA HCAL facilitates the growth and metastasis of hepatocellular carcinoma by acting as a ceRNA of LAPTM4B. Mol Ther Nucleic Acids. 2017;9:440–451. doi:10.1016/j.omtn.2017.10.01829246322
   PubMedGoogle Scholar
• Terashima M, Tange S, Ishimura A, Suzuki T. MEG3 long noncoding RNA contributes to the epigenetic regulation of epithelial-mesenchymal transition in lung cancer cell lines. J Biol Chem. 2017;292(1):82–99. doi:10.1074/jbc.M116.75095027852821
   PubMed Web of Science ®Google Scholar
• Matsumura K, Kawasaki Y, Miyamoto M, et al. The novel G-quadruplex-containing long non-coding RNA GSEC antagonizes DHX36 and modulates colon cancer cell migration. Oncogene. 2017;36(9):1191–1199. doi:10.1038/onc.2016.28227797375
   PubMed Web of Science ®Google Scholar
• Wang M, Dong X, Feng Y, Sun H, Shan N, Lu T. Prognostic role of the long non-coding RNA, SPRY4 intronic transcript 1, in patients with cancer: a meta-analysis. Oncotarget. 2017;8(20):33713–33724. doi:10.18632/oncotarget.1673528410241
   PubMedGoogle Scholar
• Tian GW, Li N, Xin Y. Prognostic and clinicopathological significance of CCAT2 in Chinese patients with various tumors. Int J Biol Markers. 2017;32(3):e344–e351. doi:10.5301/ijbm.500028128623646
   PubMed Web of Science ®Google Scholar
• Ji P, Diederichs S, Wang W, et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene. 2003;22(39):8031–8041. doi:10.1038/sj.onc.120692812970751
   PubMed Web of Science ®Google Scholar
• Eissmann M, Gutschner T, Hammerle M, et al. Loss of the abundant nuclear non-coding RNA MALAT1 is compatible with life and development. RNA Biol. 2012;9(8):1076–1087. doi:10.4161/rna.2108922858678
   PubMed Web of Science ®Google Scholar
• Wang Z, Katsaros D, Biglia N, et al. High expression of long non-coding RNA MALAT1 in breast cancer is associated with poor relapse-free survival. Breast Cancer Res Treat. 2018;171(2):261–271. doi:10.1007/s10549-018-4839-229845475
   PubMed Web of Science ®Google Scholar
• Li C, Cui Y, Liu LF, et al. High expression of long noncoding RNA MALAT1 indicates a poor prognosis and promotes clinical progression and metastasis in bladder cancer. Clin Genitourin Cancer. 2017;15(5):570–576. doi:10.1016/j.clgc.2017.05.00128648755
   PubMed Web of Science ®Google Scholar
• Malakar P, Shilo A, Mogilevsky A, et al. Long noncoding RNA MALAT1 promotes hepatocellular carcinoma development by SRSF1 upregulation and mTOR activation. Cancer Res. 2017;77(5):1155–1167. doi:10.1158/0008-5472.CAN-16-150827993818
   PubMed Web of Science ®Google Scholar
• Zhuang M, Zhao S, Jiang Z, et al. MALAT1 sponges miR-106b-5p to promote the invasion and metastasis of colorectal cancer via SLAIN2 enhanced microtubules mobility. EBioMedicine. 2019;41:286–298. doi:10.1016/j.ebiom.2018.12.04930797712
   PubMed Web of Science ®Google Scholar
• Liu Y, Jiang M, Ni L, Xu Z, Xu J. Diagnostic value of serum carcinoembryonic antigen and carbohydrate antigen 724 combined with long non-coding RNA MALAT1 detection in gastric cancer. Cancer Res Clin. 2019;31:88–92.
   Google Scholar
• Yazarlou F, Modarressi MH, Mowla SJ, et al. Urinary exosomal expression of long non-coding RNAs as diagnostic marker in bladder cancer. Cancer Manag Res. 2018;10:6357–6365. doi:10.2147/CMAR.S18610830568497
   PubMed Web of Science ®Google Scholar
• Mei H, Liu Y, Zhou Q, Hu K, Liu Y. Long noncoding RNA MALAT1 acts as a potential biomarker in cancer diagnosis and detection: a meta-analysis. Biomark Med. 2019;13(1):45–54. doi:10.2217/bmm-2018-012830561226
   PubMed Web of Science ®Google Scholar
• Rutter CM, Gatsonis CA. A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Stat Med. 2001;20(19):2865–2884. doi:10.1002/sim.94211568945
   PubMed Web of Science ®Google Scholar
• Wu J, Yu L, Wang X, Li J, Zhu M, Yan F. Expression and clinical significance of plasma MALAT1 in patients with breast cancer. Chin J Lab Med. 2018;41:92–96.
   Google Scholar
• Wang J, Zhao S, Ouyang S, Liao L. Expression and clinical significance of plasma long non-coding RNA MALAT1 in patients with oral squamous cell carcinoma. J Pract Stomatol. 2018;34:188–192.
   Google Scholar
• Li Z, Zhou J, Zhou L, Yang H, Li M. Expression and clinical significance of long non-coding RNA MALAT1 in breast cancer. J Med Res. 2018;47:79–81.
   Google Scholar
• Huang SK, Luo Q, Peng H, et al. A panel of serum noncoding RNAs for the diagnosis and monitoring of response to therapy in patients with breast cancer. Med Sci Monit. 2018;24:2476–2488. doi:10.12659/MSM.90945329683112
   PubMed Web of Science ®Google Scholar
• Zhan Y, Du L, Wang L, et al. Expression signatures of exosomal long non-coding RNAs in urine serve as novel non-invasive biomarkers for diagnosis and recurrence prediction of bladder cancer. Mol Cancer. 2018;17(1):142. doi:10.1186/s12943-018-0893-y30268126
   PubMedGoogle Scholar
• Wang WW, Zhou XL, Song YJ, Yu CH, Zhu WG, Tong YS. Combination of long noncoding RNA MALAT1 and carcinoembryonic antigen for the diagnosis of malignant pleural effusion caused by lung cancer. Onco Targets Ther. 2018;11:2333–2344. doi:10.2147/OTT.S15755129731641
   PubMed Web of Science ®Google Scholar
• He B, Zeng J, Chao W, et al. Serum long non-coding RNAs MALAT1, AFAP1-AS1 and AL359062 as diagnostic and prognostic biomarkers for nasopharyngeal carcinoma. Oncotarget. 2017;8(25):41166–41177. doi:10.18632/oncotarget.1708328467811
   PubMedGoogle Scholar
• Huo Y, Li Q, Wang X, et al. MALAT1 predicts poor survival in osteosarcoma patients and promotes cell metastasis through associating with EZH2. Oncotarget. 2017;8(29):46993–47006. doi:10.18632/oncotarget.1655128388584
   PubMedGoogle Scholar
• Zidan HE, Karam RA, El-Seifi OS, Abd Elrahman TM. Circulating long non-coding RNA MALAT1 expression as molecular biomarker in Egyptian patients with breast cancer. Cancer Genet. 2018;220:32–37. doi:10.1016/j.cancergen.2017.11.00529310836
   PubMed Web of Science ®Google Scholar
• Han C. The expression and clinical significance of long non-coding RNA MALAT1 in endometrial cancer. Chin J Family Plann Gynecotokology. 2016;8:51–55.
   Google Scholar
• Wen Z, Li X. Diagnostic value of long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 in serum for clinical diagnosis of lung cancer. J Clin Pulm Med. 2016;21:2154–2158.
   Google Scholar
• Duan W, Du L, Jiang X, et al. Identification of a serum circulating lncRNA panel for the diagnosis and recurrence prediction of bladder cancer. Oncotarget. 2016;7(48):78850–78858. doi:10.18632/oncotarget.1288027793008
   PubMedGoogle Scholar
• Peng H, Wang J, Li J, et al. A circulating non-coding RNA panel as an early detection predictor of non-small cell lung cancer. Life Sci. 2016;151:235–242. doi:10.1016/j.lfs.2016.03.00226946307
   PubMed Web of Science ®Google Scholar
• Ren S, Wang F, Shen J, et al. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. Eur J Cancer. 2013;49(13):2949–2959. doi:10.1016/j.ejca.2013.04.02623726266
   PubMed Web of Science ®Google Scholar
• Weber DG, Johnen G, Casjens S, et al. Evaluation of long noncoding RNA MALAT1 as a candidate blood-based biomarker for the diagnosis of non-small cell lung cancer. BMC Res Notes. 2013;6(1):518. doi:10.1186/1756-0500-6-51824313945
   PubMedGoogle Scholar
• Liao K, Lin Y, Gao W, et al. Blocking lncRNA MALAT1/miR-199a/ZHX1 axis inhibits glioblastoma proliferation and progression. Mol Ther Nucleic Acids. 2019;18:388–399. doi:10.1016/j.omtn.2019.09.00531648104
   PubMedGoogle Scholar
• Hu Y, Lin J, Fang H, et al. Targeting the MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in multiple myeloma. Leukemia. 2018;32(10):2250–2262. doi:10.1038/s41375-018-0104-229632340
   PubMed Web of Science ®Google Scholar
• Qiu JJ, Lin XJ, Tang XY, Zheng TT, Lin YY, Hua KQ. Exosomal metastasis associated lung adenocarcinoma transcript 1 promotes angiogenesis and predicts poor prognosis in epithelial ovarian cancer. Int J Biol Sci. 2018;14(14):1960–1973. doi:10.7150/ijbs.2804830585260
   PubMed Web of Science ®Google Scholar
• Li ZX, Zhu QN, Zhang HB, Hu Y, Wang G, Zhu YS. MALAT1: a potential biomarker in cancer. Cancer Manag Res. 2018;10:6757–6768. doi:10.2147/CMAR.S16940630584369
   PubMed Web of Science ®Google Scholar